Earnings from continuing operations at Swiss pharmaceutical firm Novartis grew from last year, the firm revealed in results ...

AbbVie’s ABBV 2024 revenue grew 4.6% on a constant currency basis, with 2025 guidance of 5.7% growth and new 2027 guidance for combined sales of immunology drug Skyrizi and Rinvoq of $31 billion (up ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

China could be leading the charge, but the US, Canada, and Europe won’t be far behind.

Q4 2024 Management View CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and ...

Viavi Solutions expects $276 million to $288 million in Q3 FY25 revenue. The EPS guidance of $0.10 to $0.13 also beats analyst expectations.

The Coors Light manufacturer’s 8.5% stake in the nonalcoholic carbonated mixer, worth $89 million, further builds on its long-term strategy of increasing its exposure beyond beer.

Microsoft announces Small, Medium Enterprises and Channel, SME&C, headed by President Ralph Haupter, replaced as EMEA leader ...

Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 01/01/1970 12:00 am ...

Discretionary categories like luxury and big ticket home purchases performed disproportionately poorly as inflation remained ...

General Dynamics faces challenges in the aerospace and submarine segments, impacting performance, but growth expected, ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...